[
    [
        {
            "time": "2022-01-03",
            "original_text": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Gains",
                    "Market Dips"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-01-04",
            "original_text": "Why Foghorn Therapeutics Blasted 55% Higher Today",
            "features": {
                "keywords": [
                    "Foghorn Therapeutics",
                    "Blasted",
                    "Higher"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Foghorn Therapeutics Blasted 55% Higher Today",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-01-05",
            "original_text": "Calamos Growth and Income Portfolio Buys Abbott Laboratories, Huntington Bancshares Inc, Eli ...",
            "features": {
                "keywords": [
                    "Calamos Growth",
                    "Abbott Laboratories",
                    "Huntington Bancshares",
                    "Eli"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Calamos Growth and Income Portfolio Buys Abbott Laboratories, Huntington Bancshares Inc, Eli ...",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2022-01-06",
            "original_text": "Eli Lilly hikes quarterly dividend 15%",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "hikes",
                    "quarterly dividend",
                    "15%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly hikes quarterly dividend 15%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-01-07",
            "original_text": "T. Rowe Price Exchange-Traded Funds, Inc. Buys Microsoft Corp, Amazon.",
            "features": {
                "keywords": [
                    "T. Rowe Price",
                    "Microsoft Corp",
                    "Amazon"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "T. Rowe Price Exchange-Traded Funds, Inc. Buys Microsoft Corp, Amazon.",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2022-01-08",
            "original_text": "Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend",
            "features": {
                "keywords": [
                    "Lilly",
                    "Dividend Increase",
                    "First-Quarter 2022"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2022-01-09",
            "original_text": "Foghorn Forms Oncology Partnership With Eli Lilly. The Stock Is Soaring.",
            "features": {
                "keywords": [
                    "Foghorn",
                    "Oncology Partnership",
                    "Eli Lilly",
                    "Soaring"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Foghorn Forms Oncology Partnership With Eli Lilly. The Stock Is Soaring.",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-01-10",
            "original_text": "Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal",
            "features": {
                "keywords": [
                    "Lilly",
                    "Metabolic Disorders",
                    "Therapy Development Deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-01-11",
            "original_text": "Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly",
            "features": {
                "keywords": [
                    "Foghorn Therapeutics",
                    "Stock Surges",
                    "$1.5B",
                    "Cancer Pact",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-01-12",
            "original_text": "Foghorn Therapeutics shares soar 26% premarket on news of cancer collaboration with Eli Lilly",
            "features": {
                "keywords": [
                    "Foghorn Therapeutics",
                    "soar",
                    "cancer collaboration",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Foghorn Therapeutics shares soar 26% premarket on news of cancer collaboration with Eli Lilly",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2022-01-13",
            "original_text": "Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform",
            "features": {
                "keywords": [
                    "Lilly",
                    "Foghorn",
                    "Strategic Collaboration",
                    "Oncology Targets",
                    "Gene Traffic Control® Platform"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-01-14",
            "original_text": "Foghorn Therapeutics Jumps on Eli Lilly Collaboration",
            "features": {
                "keywords": [
                    "Foghorn Therapeutics",
                    "Jumps",
                    "Eli Lilly Collaboration"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Foghorn Therapeutics Jumps on Eli Lilly Collaboration",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]